Genmab Corp (GMAB): יחס חוב לטווח ארוך להון

Genmab A/S (GMAB) relies on its unique DuoBody system and stable revenue from Darzalex to advance its oncology pipeline. However, geopolitical tensions and sanctions are currently hindering biomaterial logistics and global trials. The confirmed price history on this chart, where the indicator stands at 0.88, underscores the effectiveness of the Danish management, which has successfully balanced scientific research with the commercialization of antibodies.

This metric determines the proportion of long-term borrowings relative to equity, measuring the degree of financial leverage and the stability of the funding structure during periods of rate volatility. By analyzing the long-term debt-to-equity ratio, investors assess the ability of Genmab A/S (GMAB) to scale oncology developments, utilizing colossal royalties from Darzalex to optimize the debt load without compromising investment potential.